Trial Profile
A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate 0.2% Nanoemulsion Eye Drops in Patients With Dry Eye Disease (DED)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Brimonidine/loteprednol-etabonate (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Ocugen
- 30 Jun 2020 Status changed from recruiting to completed.
- 08 Oct 2018 New trial record
- 01 Oct 2018 According to an Ocugen media release, topline data are expected in in the second half of 2019.